Abbott Pakistan’s profit surge masks a volume problem

For Abbott Laboratories Pakistan, 2025 was the sort of year that pharmaceutical companies in Pakistan had spent much of the previous decade waiting for. Revenue rose, margins widened, profits surged, dividends increased and the company entered 2026 with earnings momentum still intact. Yet beneath the surface of the numbers lies a less comfortable reality: Pakistan’s pharma companies may finally have regained pricing power, but their customers have not regained purchasing power at the same pace.

Abbott Laboratories Pakistan reported earnings per share of Rs81.37 for calendar year 2025, up from Rs53.46 in the previous year, according to a Chase Securities corporate briefing note dated May 25, 2026. In the latest quarter covered by the briefing, EPS roughly doubled to Rs26.57 from Rs13.13 in the same period a year earlier. For a company that already sits among the more recognisable multinational names on the Pakistan Stock Exchange, the improvement was substantial.